Search

Displaying results 7501 - 7510 of 9886 in total
  1. Drug

    AC3056

    go.drugbank.com/drugs/DB05230
    Experimental

    AC3056 is a non-peptide antioxidant that acts as an inhibitor of vascular cell adhesion molecule expression originally developed by Aventis Pharmaceuticals.

  2. Drug

    XL019

    go.drugbank.com/drugs/DB05243
    Investigational

    XL019 is a selective inhibitor of the cytoplasmic tyrosine kinase JAK2. An IND for XL019 was filed by Exelixis in May 2007.

  3. Drug

    Telapristone acetate

    go.drugbank.com/drugs/DB05253
    Investigational

    Telapristone acetate, an orally-available, selective progesterone receptor modulator, is in development to alleviate symptoms associated with both uterine fibroids and endometriosis.

  4. Drug

    Gallium nitrate

    go.drugbank.com/drugs/DB05260
    ApprovedInvestigational

    Gallium nitrate is a nitrate salt of [DB14524], a heavy metal that has been used as a diagnostic agent.[A260816] Gallium nitrate is reported to possess antiresorptive and hypocalcemic effects on bone. … [A17097] GANITE, a product of gallium nitrate previously used to treat cancer-related hypercalcemia, was discontinued from marketing in the US for reasons other than safety or effectiveness.

  5. Drug

    Anecortave acetate

    go.drugbank.com/drugs/DB05288
    Investigational

    Anecortave acetate (Retaane) is an analog of cortisol acetate; among the modifications to the steroid are the removal of the 11ß hydroxyl OH group and an addition of a 21-acetate group. … As a result of these modifications, anecortave acetate lacks the typical antiinflammatory and immunosuppressive properties of glucocorticoids.Alcon Inc. is developing and marketing Retaane.

  6. Drug

    Tarenflurbil

    go.drugbank.com/drugs/DB05289
    Investigational

    It is a selective amyloid lowering agent (SALA) that reduces levels of the toxic peptide amyloid beta 42 (Aβ42) in cultured human cells and in animal models.

  7. Drug

    SPP 301

    go.drugbank.com/drugs/DB05290
    Investigational

    SPP301 (Avosentan) is a potent and highly selective ET[A] receptor blocker and is clinically investigated in diabetic nephropathy.

  8. Drug

    IDM-2

    go.drugbank.com/drugs/DB05293
    Experimental

    IDM-2 is composed of Monocyte-derived Activated Killer (MAK) cells. IDM produces MAK cells from the patient's own white blood cells by activating these cells ex vivo to allow them to recognize and destroy tumor cells.

  9. Drug

    PTI-801

    go.drugbank.com/drugs/DB05300
    Investigational

    It is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist. … PTI-801 represents a new class of drugs to treat pain. PTI-801 can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of oxycodone.

  10. Drug

    Rusalatide

    go.drugbank.com/drugs/DB05309
    Investigational

    TP508 is a non-proteolytic synthetic peptide representing the portion of human thrombin originally identified as the fibroblast high-affinity receptor binding domain.